61. 自己免疫性溶血性貧血 Autoimmune hemolytic anemia Clinical trials / Disease details
臨床試験数 : 137 / 薬物数 : 127 - (DrugBank : 55) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 153
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04802057 (ClinicalTrials.gov) | March 22, 2021 | 15/3/2021 | Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With BIVV020 | An Open Label, Long Term, Safety and Tolerability Study of Patients With Cold Agglutinin Disease Previously Treated With BIVV020 | Autoimmune Haemolytic Anaemia | Drug: BIVV020 | Bioverativ, a Sanofi company | NULL | Active, not recruiting | 18 Years | N/A | All | 4 | Phase 1 | Germany;Italy;Netherlands;Norway;United Kingdom |
| 2 | NCT04269551 (ClinicalTrials.gov) | June 15, 2020 | 29/1/2020 | A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease | A Multicenter, Phase 1b, Open Label, Nonrandomized, Single Dose Study Evaluating the Safety, Tolerability and Activity of BIVV020 in Adults With Cold Agglutinin Disease | Autoimmune Haemolytic Anaemia | Drug: BIVV020 | Bioverativ, a Sanofi company | NULL | Completed | 18 Years | N/A | All | 12 | Phase 1 | United States;Germany;Italy;Netherlands;Norway;United Kingdom;Canada;Spain |